Korean J Biol Psychiatry.
2016 Feb;23(1):18-23. 10.0000/kjbp.2016.23.1.18.
Mammalian Target of Rapamycin Signaling Pathways and Depression
- Affiliations
-
- 1Department of Psychiatry, Haeundae Paik Hospital and College of Medicine, Inje University, Busan, Korea. iybihwc@naver.com
- 2Paik Institute for Clinical Research, Inje University College of Medicine, Busan, Korea.
- 3Department of Health Science and Technology, Graduate School of Inje University, Busan, Korea.
- KMID: 2251107
- DOI: http://doi.org/10.0000/kjbp.2016.23.1.18
Abstract
- Depression is a complicated psychiatric illness with severe consequences. Despite recent advanced achievements of molecular neurobiology, pathophysiology of depression has not been well elucidated. Among new findings of pathophysiology of depression, the possible fast antidepressant effect by N-methyl-D-asparate receptor antagonist, such as ketamine, is regarded as a promising treatment target of depression. Ketamine stimulates the mammalian target of rapamycin (mTOR) signaling pathway and activation of mTOR signaling pathway may be a key mechanism of the antidepressant effect of ketamine. Thus, this review describes the role of mTOR signaling in the pathophysiology of depression and developing a new treatment target of depression.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Where is the Mechanistic Target of Rapamycin Signaling Pathway in Depression?
- The role of amino acid-induced mammalian target of rapamycin complex 1(mTORC1) signaling in insulin resistance
- Autophagy and Neurodegenerative Diseases
- Understanding the Molecular Biology in the Pathogenesis of Depression
- Frontier of Epilepsy Research - mTOR signaling pathway
